Related news from
Thu, 16 Oct 2025 13:00:00 +0000	Cycle Pharmaceuticals Launches Its First Oncology Product, PHYRAGO™ (dasatinib) Tablets, in the US DETROIT, October 16, 2025--Cycle Pharmaceuticals announces the launch of PHYRAGO, its first oncology product in the US. PHYRAGO is launched in partnership with Handa Therapeutics, LLC, and will be exclusively available through specialty pharmacy Onco360® with a specialty distribution network from McKesson, Cencora, and Cardinal Health.
Thu, 16 Oct 2025 13:00:00 +0000	IntrinsiQ Specialty Solutions Expands Data Capabilities to Empower Biopharmaceutical Manufacturers and Physicians with Actionable Insights to Improve Patient Outcomes CONSHOHOCKEN, Pa., October 16, 2025--IntrinsiQ® Specialty Solutions (IntrinsiQ), a leader in data analytic solutions, and part of Cencora, can now offer expanded data and insights for oncology, retina and other therapeutic areas. As part of this expansion, IntrinsiQ is now also offering oncology biomarker data, enabling physicians to transition from a generalized treatment approach to precision medicine. This critical data allows physicians to tailor cancer therapies to the individual needs of e
Tue, 14 Oct 2025 16:47:00 +0000	The Market Took a Hit. These 6 Stocks Can Sidestep the Wreckage. Those looking to buy stocks right now should look for the ones that aren’t correlated to the artificial intelligence trade.
Tue, 14 Oct 2025 04:43:12 +0000	3 Market-Beating Stocks Worth Your Attention Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three for years on end are almost always the legendary stocks that return 100 times your money.
Tue, 14 Oct 2025 04:03:14 +0000	3 Reasons COR Has Explosive Upside Potential Even though Cencora (currently trading at $315 per share) has gained 10.8% over the last six months, it has lagged the S&P 500’s 22.9% return during that period. This might have investors contemplating their next move.
Mon, 13 Oct 2025 18:08:51 +0000	Does Cencora’s Strong 42% Rally Signal More Growth Ahead in 2025? If you’re standing at a crossroads, wondering what to do with Cencora stock, you’re not alone. With shares closing recently at $318.00 and quietly notching up a 42.6% gain over the past year, there’s a real sense of momentum. The stock outperformed in the last five years too, leaping an astonishing 244.5%. That’s a growth story that’s caught more than a few eyes. Even over the most recent periods, Cencora’s consistency stands out, with a 4.2% uptick in just the last week and 5.1% over the...
Mon, 13 Oct 2025 13:45:02 +0000	Here's Why Cencora (COR) is a Strong Growth Stock The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Fri, 10 Oct 2025 19:20:50 +0000	Bitcoin Miner Leads Two Health Care Stocks To New Highs Core Scientific hit an all-time high in Friday's stock market. Shares are on a three-day winning streak and just above a cup base's buy point of 18.21, making the company one that's reaching new highs and worth watching. Its relative strength line is rising while the Relative Strength Rating of 92 shows that the stock has performed better than the majority of stocks in the Investor's Business Daily database over the past 52 weeks.
Fri, 10 Oct 2025 13:40:02 +0000	Why This 1 Value Stock Could Be a Great Addition to Your Portfolio Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Wed, 08 Oct 2025 15:48:00 +0000	McKesson Bets on Oncology, Biopharma as It Streamlines Portfolio MCK is transforming from a traditional distributor into a specialty-driven healthcare solutions leader, focusing on oncology, biopharma services and automation while preparing to separate its Medical-Surgical unit.
Mon, 06 Oct 2025 20:30:00 +0000	Cencora Announces Date and Time for Fourth Quarter Fiscal 2025 Earnings Release CONSHOHOCKEN, Pa., October 06, 2025--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Fourth Quarter of Fiscal 2025 on Wednesday, November 5, 2025, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on November 5, 2025.
Mon, 29 Sep 2025 19:05:24 +0000	Cardinal Health Stock Scores Relative Strength Rating Upgrade Cardinal Health shows rising price performance, earning an upgrade to its IBD Relative Strength Rating
Mon, 29 Sep 2025 04:42:25 +0000	2 Large-Cap Stocks with Exciting Potential and 1 We Find Risky Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players.
Sat, 27 Sep 2025 14:13:48 +0000	Is Cencora (COR) Undervalued? Exploring the Quiet Rally and What It Means for Investors Cencora (COR) has caught the attention of investors this week, but not because of a single seismic event. Sometimes, the absence of headline-grabbing news is its own story, especially for a company with Cencora’s track record. When the stock quietly moves without a dramatic catalyst, it raises interesting questions about how the market is digesting the business’s fundamentals and future growth potential. Over the past year, Cencora’s share price has delivered a 38% total return, outpacing...
Fri, 26 Sep 2025 15:34:03 +0000	Why Cencora (COR) is a Top Growth Stock for the Long-Term The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Fri, 26 Sep 2025 04:37:55 +0000	1 Surging Stock with Exciting Potential and 2 We Find Risky The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.
Tue, 23 Sep 2025 22:58:00 +0000	Kroll Settlement Administration Announces that The Lash Group, LLC Has Reached a Settlement Regarding a Data Security Incident CONSHOHOCKEN, Pa., September 23, 2025--The following statement is being issued by Kroll Settlement Administration regarding the Cencora Data Security Incident Settlement.
Tue, 23 Sep 2025 20:45:00 +0000	Top Analyst Reports for Apple, Eli Lilly & Chevron Apple grows Services with over 1B subscribers, while Eli Lilly and Chevron face mixed industry and market dynamics.
Tue, 23 Sep 2025 19:30:43 +0000	Why Cencora (COR) Stock Is Trading Up Today Shares of healthcare distributor Cencora (NYSE:COR) jumped 4.5% in the afternoon session after peer company McKesson raised its long-term earnings growth outlook, boosting investor sentiment across the pharmaceutical distribution sector.
Tue, 23 Sep 2025 13:00:00 +0000	nuVizz to Showcase B2B Last-Mile Delivery Strategies at CSCMP EDGE 2025 nuVizz joins industry leaders to share insights on achieving delivery resilience, agility and performance during an exclusive session on optimizing B2B last-mile logisticsATLANTA, Sept. 23, 2025 (GLOBE NEWSWIRE) -- nuVizz, a leading innovator in last-mile transportation management solutions (TMS), announced today it will be presenting alongside key partners Ford Motor Company, GEODIS, Cencora and Bart De Muynck LLC at the upcoming CSCMP EDGE 2025 Conference. The session, titled “How to Build Res

If you are already a Value Forum member but are not logged on, click here to log on. If you are a guest, thank you for visiting ValueForum -- click here for information about guest access or click here to join -- a Trial Pass can be purchased for $6.99 to help you decide if you want to commit to longer term membership. Did you know there are customized portals into VF like REITs.ValueForum.com and also My ValueForum which lets you customize your VF experience to the posters and topics that most interest you!